NeuroPro

NeuroPro is a biotechnology company focused on developing novel small molecule therapeutics for the treatment of neurodegenerative and neurological disorders. The company's primary research centers on the inhibition of neuropsin (Kallikrein-8), a serine protease that plays a critical role in synaptic plasticity and has been implicated in the pathogenesis of Alzheimer's disease and epilepsy. By targeting neuropsin, NeuroPro aims to provide disease-modifying treatments that can preserve cognitive function and reduce seizure activity. The company is currently advancing its lead candidates through pre-clinical development, leveraging deep expertise in protease biology and neuroscience. NeuroPro has been supported by initiatives such as Johnson & Johnson Innovation (JLABS), highlighting its potential in the competitive neurodegeneration space.